N P S. National Prescribing Service Limited
|
|
- Kory Russell
- 8 years ago
- Views:
Transcription
1 N P S National Prescribing Service Limited No. 7 February 2000 Prescribing Practice Review In this issue we include information to assist you to conduct a formal medication review with your patients. As GPs we informally review a patients medication every time a prescription is written. The Enhanced Primary Care new MBS items offer opportunities to conduct a formal medication review The review is part of a Health Assessment, Care Plan or Case Conference in addition to long consultations in the surgery or home. A medication review will be annual where it is part of the Health Assessment or DVA Health Assessment, however should be done at any time that it is clinically indicated. Medication review is a formalised and comprehensive review process The aim is to optimise the therapeutic management of your patients by assessing any need for changes in medications and ensuring the patient s understanding of the medication regimen. Provide reviews for patients at risk Medication misadventure is a common cause of morbidity and at times mortality. Suggested triggers for medication review are provided inside. Ask the patient about all medications and provide counselling on use Evidence shows we often are not aware of all the medications the patient is taking 1 especially over-the-counter and complementary medicines.the review involves a complete medication history with the patient and provision of education about wise use of medicines. Please find enclosed PPR issue no. 7, a medication review form and a sample leaflet to copy and give to patients explaining the purpose of the exercise and asking the them to bring all the medications to the medication review appointment. Yours sincerely Dr Stephen Phillips Chair, NPS Board Supporting quality prescribing in Australia National Prescribing Service Limited ACN l 9 Leichhardt St Darlinghurst NSW 2010 Phone: l Fax:
2 NP SPPR National Prescribing Service Ltd No. 7 February 2000 Prescribing Practice Review What is a medication review? You probably review each patient s medication every time you write a new prescription. In this PPR medication review is used to refer to a retrospective critical review of all prescribed, over-thecounter and complementary (herbal) medications. It is undertaken to optimise therapy and minimise medication related problems. A medication review may be undertaken in the surgery or home. Desirable frequency will vary from patient-to-patient. For example: for elderly patients and/or those with chronic but stable illness, an annual review may be appropriate; for patients with unstable disease, review at critical times such as on discharge from hospital. Medication reviews are widely carried out by: GP s and accredited pharmacists working together as a primary health care team; by GP s, accredited pharmacists and nurses in institutional settings; and by clinical pharmacists, medical specialists and nurses in a hospital setting. Reviews may be undertaken by the GP alone, using drug information resources however, it is often more valuable to involve an accredited, clinical or appropriate community pharmacist, medical specialist or community nurse. Medication review may be conducted as part of the new Medicare Benefit items. 1. Health Assessment Items Health assessment for the elderly in the surgery or patient s home, for patients aged 75 years and over (or 55 years and older for Aboriginal and Torres Strait Islander people). Must include a medication review. 2. Care Plans Items For patients with chronic illness and multidisciplinary care needs involving 2 health care providers. Includes discharge care plans from hospital.the patient must agree to the management goals. 3. Case Conferencing Items Case conferencing with other providers in planning care for people with chronic conditions and multidisciplinary care needs. Includes discharge case conferencing from hospital. 4. Other As part of a long consultation or home visit where clinically appropriate.as part of a DVA Health Assessment.
3 Medication review Who should have a medication review? The triggers in the table below identify patients who may benefit from a comprehensive medication review and show how they can be used within the framework of the new MBS items. Triggers for medication review Health Care Case Long cons./ assessment plan conference home visit Annual Health Assessment or medicine check New patient to your practice Polypharmacy -patient using 5 medications or 12 daily doses Patient using psychoactive medications Patient with 3 co-existing disease states Elderly people with cognitive impairment, living alone Patient with compliance/concordance problems Patient with a complicated medication regimen - especially if taking drugs with high risk of adverse effects or which require therapeutic monitoring e.g. amiodarone, warfarin Post hospital discharge - especially if medication has changed Multiple prescribers including specialists and/or other GPs Recently initiated medications or 4 changes to medication regimen in last year Adverse event e.g. recent fall, allergy Patient has unexpected response to medication Change in health status In response to a clinical audit In response to a computer alert In response to abnormal laboratory/ clinical chemistry results Quick checklist for medication review Gain consent and cooperation of the patient, explain what you hope to achieve Allocate a specific appointment and allow sufficient time e.g. within health assessment or book a long consultation Take an accurate and complete medication history, preferably sighting all medications It may also be helpful to see unfilled prescriptions currently held by the patient Complete the medication review form (provided) with the patient Clarify the treatment goal for each medication e.g. reduction of blood pressure to target level Identify potential problems and assess clinical relevance Follow up on actions and continue to monitor. 2
4 In more detail. 1. Taking a medication history Use a non-judgmental technique and open-ended questions. Facilitated by physical inspection of all medications (the brown paper bag approach). Ask about: all prescription drugs, prescribed by you and other doctors over-the-counter (non-prescription) medications complementary (herbal, alternative, vitamin) products eye drops, inhalers, patches and topical treatments, as patients often forget to mention these also, alcohol, tobacco and illicit drugs. Ask about the patient s pattern of medication use For example: frequency, regularity, method and reason for use. Ask about perceived drug efficacy. Record all adverse drug events For example: allergic reactions, adverse reactions and other possible related events, such as falls. Discard any out-of-date medications or repeat prescriptions for drugs which are no longer needed. 2. Problem identification 2,3,4 The aim is to solve or avoid any medication-related problem/s that interfere with the desired patient outcome. Some problems may require further investigation. Are there any untreated indications? Is this the most appropriate drug for the indication(s)? Is the drug effective and is the treatment goal being achieved? Have there been changes in evidence/best practice since it was first prescribed? Have appropriate non-drug measures been instituted? Is there an ongoing need for this drug? Have any drugs been initiated to treat adverse drug effects? Is the dose, frequency and appropriate? Has the dose been individualised for the patient? Consider weight, age, renal function, etc. Is there duplication? Drugs in same therapeutic class, generic-brand duplication Does the patient have contraindications to any medications? Consider disease states, pregnancy, renal function, liver function, drug allergies etc and consider therapeutic alternatives Are there any actual or potential adverse effects occurring? Are there any clinically important interactions (drug-drug, drug-food)? Is the drug effect and/or side effects monitored appropriately? Are there any problems with compliance/concordance? Could the regimen be simplified? Is the regimen cost-effective for the patient and taxpayer? Continues on back page... 3
5 Continued from page Action/plan 3,4 In most cases no change is required i.e. treatment is appropriate and therapeutic outcomes have been achieved Dose/frequency changes For example: doses are sub-therapeutic or medication is taken improperly Discontinue medication For example: an inappropriate drug is being used Add an alternative or a new medication or institute non-drug therapy For example: drugs used are ineffective or therapeutic outcome has not been achieved Document in medical record Implement monitoring Medication counselling/instructions for patient/carer Research information on drug Such as approved product information, reference texts, drug information service, manufacturer, specialist, community or clinical pharmacist, clinical pharmacologist Contact or refer to other health professional For example: pharmacist, community nurse, other treating doctors, hospital/health service. 4. Communication with the patient Explain the purpose of the medication review and the benefit for the patient, this will establish trust to ensure complete medication history and disclosure of compliance Does the patient understand how to take the medication and any special precautions? Check that written consumer medicine information has been provided where appropriate Check comprehension and literacy regarding labelling, consumer medicines information Consider appropriate aids for compliance, equipment for administration or monitoring Referral to a pharmacist may assist, also check use and maintenance of equipment such as nebulisers, spacers, peak flow meters, and blood glucose level meter. Acknowledgment The medication review form design is based on the work of medication review projects conducted in Divisions of General Practice (DiNCQUM GP with Central Coast, Central Sydney, Fremantle Regional and Osborne Divisions of General Practice; Domiciliary Project, University of Sydney with St. George and Canterbury Divisions of General Practice; and QUM-Medication Review in Inner SE Melbourne Division of General Practice). References: 1. Atkin PA, Stringer RS, Duffy JB, Elion C, Ferraris CS et al. The influence of information provided by patients on the accuracy of medication records. MJA 1998;169: Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam G. Drug-related problems: their structure and function. Annals of Pharmacotherapy 1990;24: Mant A. Thinking about prescribing; a handbook for quality use of medicines. Sydney: McGraw-Hill Co.; Kradjan WA, Koda-Kimble MA, Young LY, Guglielmo BJ. Assessment of therapy and pharmaceutical care. In: Young LY, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs. 6th ed. Vancouver: Applied Therapeutics Inc; Australian Medicines Handbook. 1st ed. Adelaide: Australian Medicines Handbook; The information contained in this material is derived from a critical analysis of a wide range of authoritative evidence. Any treatment decisions based on this information should be made in the context of the individual clinical circumstances of each patient N P S National Prescribing Service Limited Our goal To improve health outcomes for Australians through prescribing that is : safe effective cost-effective. Our programs To enable prescribers to make the best prescribing decisions for their patients, the NPS provides information education support and other resources. National Prescribing Service ACN Level 1/31 Buckingham Street, Surry Hills 2010 Phone: l Fax: l nps@zip.com.au
6 Date: _ Medical record/file no: Patient name: Form N P S Medication History Medication Problems Plan of Action Medication Prescribed dose/ Actual dose/ Treatment goal Actions/instructions to patient eg: (generic/brand frequency frequency/ (reason for medication) Tick those that apply dose change, cease, new medication, name and strength) method of use medication counselling, compliance aids
7 Instructions for using this form This form (consisting of two pages, this page and overleaf ) is to assist with the process of a medication review.the form is made up of 5 rows, one row for each medication. Photocopy this form as many times as is needed for each patient. Complete Patient Details Fill in the date of review, patient name and medical history in the space provided in the box opposite and at the top of the form overleaf. Medication History Take a medication history with the patient, then complete the four sections on the form, as outlined below. 1. Medication : list all medications currently used regularly or intermittently. Include all prescription drugs prescribed by you and other doctors, over-the-counter medicines and complementary medicines (herbal, alternative and vitamin perparations) as well as medications not previously recorded on your medical records. 2. Prescribed : record dose and frequency of medication as prescribed (if applicable) e.g. 10mg at night. 3. Actual : record dose and frequency of medication taken by patient eg: 10 mg at night prn when symptoms occur. 4. Therapeutic goal : record the desired clinical outcome e.g. target blood presure level, pain control. Medication Problems Tick any which apply, for other, specify problems. Plan of Action Record action plan e.g.reduce dose, order biochemistry. For further assistance or information please contact the National Prescribing Service on (02) or refer to the Prescribing Practice Review No. 7, on. Patient Details N P S Date of review: _ Patient name: Age: Weight: Allergies: History of adverse drug reactions: Alcohol and tobacco use: Renal function: Serum creatinine: Estimated Cl cr* : Liver function: *Calculating an Estimate of Renal Function 5 Renal function declines with age. The estimated creatinine clearance rather than the serum creatinine indicates renal function. Use a formula such as Cockcroft - Gault to estimate renal clearance, especially in the elderly who may have a normal serum creatinine Creatinine clearance Cl cr (ml/min) (males) = (140 age ) x (body weight (kg)) 815 x serum creatinine (mmol/l) (females) = 85% of above - Creatinine clearance <10 ml/min - - renally excreted drugs may be contraindicated - Creatinine clearance ml/min - significant dosage adjustment will be necessary for renally excreted drugs - Creatinine clearance ml/min - most renally excreted drugs will need dosage adjustment Note this formula is invalid in severe renal insufficiency or with rapidly changing renal function. Drug Interactions: See for information on interactions with the top 10 drugs used on PBS. Other resources: Australian Medicines Handbook;Therapeutic Guideline series
Medication Utilization. Understanding Potential Medication Problems of the Elderly
Medication Utilization Understanding Potential Medication Problems of the Elderly NICE - National Initiative for the Care of the Elderly WHAT ARE MEDICATION UTILIZATION PROBLEMS AMONG THE ELDERLY? A useful
More informationGuidelines on Counseling. Approved by PEIPB
Guidelines on Counseling Approved by PEIPB November 2005 1 Patient Counseling Patient counseling is a key competency element of the Pharmaceutical Care process. Given the advertising for medication in
More informationMedicines reconciliation on admission and discharge from hospital policy April 2013. WHSCT medicines reconciliation policy 1
Medicines reconciliation on admission and discharge from hospital policy April 2013 WHSCT medicines reconciliation policy 1 Policy Title Policy Reference Number Medicines reconciliation on admission and
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationRivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)
Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep
More informationClinical Intervention Definitions
Pharmacy Practice Incentive (PPI) Program Clinical Intervention Definitions $97 million over the life of the Agreement (5 years) Clinical Intervention - Definitions A clinical intervention: is a professional
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK ACAMPROSATE CALCIUM (Campral EC) for alcohol abstinence ESCA: Adjunct in the treatment of chronic alcohol dependence (under
More informationCytotoxic and Biotherapies Credentialing Programme Module 5
Cytotoxic and Biotherapies Credentialing Programme Module 5 1. Drug Dose Determination 2. Drug Calculations 3. Role of the Second Checker 4. The Checking Process At the completion of this module the RN
More informationHelping you manage your pain
Helping you manage your pain This booklet contains confidential personal information. If found, please mail to the address below. Personal details Name Address Telephone My health care team (please tick)
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationMedications: A Double-Edged Sword Family Caregiver Alliance
Any symptom in an elderly patient should be considered a drug side effect until proved otherwise. Brown University Long-term Care Quality Letter, 1995. Modern medicines have contributed to longer life
More informationNOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions
AC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions FAQ document jointly prepared by NHSGGC Haematology Service & Medicines Infmation On behalf of the Heart MCN
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationTABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS
TABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS Section 1. Authority 9-1 Section 2. Definitions 9-1 Section 3. Patient Profile Records 9-1 Section 4. Prospective
More informationClassification for Drug related problems
Classification for Drug related problems (revised 14-01-2010vm) 2003-2010 Pharmaceutical Care Network Europe Foundation This classification can freely be used in Pharmaceutical Care Research and practice,
More informationUNIVERSITY OF WISCONSIN HOSPITAL AND CLINICS DEPARTMENT OF PHARMACY SCOPE OF PATIENT CARE SERVICES FY 2014 October 1 st, 2014
UNIVERSITY OF WISCONSIN HOSPITAL AND CLINICS DEPARTMENT OF PHARMACY SCOPE OF PATIENT CARE SERVICES FY 2014 October 1 st, 2014 Department Name: Department of Pharmacy Department Director: Steve Rough, MS,
More informationRivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery
for preventing venous thromboembolism after hip or knee replacement surgery (riv-ah-rocks-ah-ban) Summary Rivaroxaban is an oral anticoagulant and the first direct factor Xa inhibitor. Rivaroxaban has
More informationGuidelines for Education Requirements for Recognition as Eligible Midwives and Accreditation Standards for programs of study leading to endorsement
Guidelines for Education Requirements for Recognition as Eligible Midwives and Accreditation Standards for programs of study leading to endorsement for scheduled medicines for Eligible Midwives 6447 Contents
More informationAdministrative Policies and Procedures for MOH hospitals /PHC Centers. TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide
Administrative Policies and Procedures for MOH hospitals /PHC Centers TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide NO. OF PAGES: ORIGINAL DATE: REVISION DATE : السیاسات
More informationProgram Approved by AoA, NCOA. Website: www.homemeds.org
MEDICATION MANAGEMENT IMPROVEMENT SYSTEM: HomeMeds SM The HomeMeds SM system is a collaborative approach to identifying, assessing, and resolving medication problems in community-dwelling older adults.
More informationGUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS
GUIDELINES GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS Preamble The American Society of Consultant Pharmacists has developed these guidelines for use of psychotherapeutic medications
More information02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
Effective June 13, 2010 02-313, 02-373, 02-380, 02-383, 02-396 Chapter 21 page 1 02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 313 BOARD OF DENTAL EXAMINERS 373 BOARD OF LICENSURE IN MEDICINE
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationCNA and NSO Risk Control Self-assessment Checklist for Nurse Practitioners 1. Self-assessment topic Yes No Actions needed to reduce risks
Risk Control Self-assessment Checklist for Nurse Practitioners This checklist is designed to help nurse practitioners evaluate risk exposures associated with their current practice. For additional nurse
More informationCLOSING THE GAP IMPROVING INDIGENOUS ACCESS TO MAINSTREAM PRIMARY CARE
CLOSING THE GAP IMPROVING INDIGENOUS ACCESS TO MAINSTREAM PRIMARY CARE FREQUENTLY ASKED QUESTIONS SECTION ONE: SECTION TWO: Determining Patient of Aboriginal and Torres Strait Island Descent. PIP Indigenous
More informationQUM and Continuity of Care A Prescribed Medicines Services and Programs
Community Pharmacy Roadmap Program Development Template Program/Service: Quadrant: 1. Program/Service Description QUM and Continuity of Care A Prescribed Medicines Services and Programs a) Background The
More informationHow Can We Get the Best Medication History?
How Can We Get the Best Medication History? Stephen Shalansky, Pharm.D., FCSHP Pharmacy Department, St. Paul s Hospital Faculty of Pharmaceutical Sciences, UBC How Are We Doing Now? Completeness of Medication
More informationStandards of Practice for Pharmacists and Pharmacy Technicians
Standards of Practice for Pharmacists and Pharmacy Technicians Introduction These standards are made under the authority of Section 133 of the Health Professions Act. They are one component of the law
More informationNational Residential Medication Chart (NRMC3) User guide for nursing and care staff
National Residential Medication Chart (NRMC3) User guide for nursing and care staff Commonwealth of Australia 2014 This work is copyright. It may be reproduced in whole or in part for study or training
More informationHealth Policy. Perceptions of economic hardship and implications for illness management: a survey of general practitioners in western Sydney.
Menzies Centre for Health Policy Perceptions of economic hardship and implications for illness management: a survey of general practitioners in western Sydney. January 2011 Dr Angela Beaton 1, Professor
More informationConcept Series Paper on Disease Management
Concept Series Paper on Disease Management Disease management is the concept of reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing
More informationBenzodiazepines Reviewing long term use: a suggested approach
NP SPPR National Prescribing Service Ltd No. 4 July 1999 Prescribing Practice Review Reviewing long term use of benzodiazepines, pp1-4 Managing the new patient with insomnia, pp5-6 Enclosed patient material
More informationMayo Clinic College of Medicine Pharmacy Services. Rotation Summary
Mayo Clinic College of Medicine Pharmacy Services Rotation Summary Rotation Title: PGY-2 Pediatric Hematology-Oncology Rotation Length: 3-6 weeks Primary Preceptor Name: Amanda Kuper, PharmD, BPCS, Ron
More informationThe Australian Healthcare System
The Australian Healthcare System Professor Richard Osborne, BSc, PhD Chair of Public Health Deakin University Research that informs this presentation Chronic disease self-management Evaluation methods
More informationMedication Management Guidelines for Nurses and Midwives
Medication Management Guidelines for Nurses and Midwives 1. Introduction As the statutory body responsible for the regulation of nursing and midwifery practice in Western Australia (WA), the Nurses & Midwives
More informationMedicines and You: A Guide for Older Adults
Medicines and You: A Guide for Older Adults Council on Family Health Provided in cooperation with U.S. Department of Health and Human Services Food and Drug Administration and the Administration on Aging
More informationUNDERSTANDING THE CONTENT OUTLINE/CLASSIFICATION SYSTEM
BOARD OF PHARMACY SPECIALTIES PHARMACOTHERAPY SPECIALIST CERTIFICATION CONTENT OUTLINE/CLASSIFICATION SYSTEM FINALIZED SEPTEMBER 2015/FOR USE ON FALL 2016 EXAMINATION AND FORWARD UNDERSTANDING THE CONTENT
More informationSaxagliptin (Onglyza) for type 2 diabetes
Saxagliptin (Onglyza) for type 2 diabetes This Medicine Update is for people who are taking, or thinking about taking, saxagliptin. Summary Saxagliptin (brand name Onglyza) is a tablet that can be used
More informationGuidelines for the Practice and Documentation of Comprehensive Medication Management in the Patient-Centered Medical Home
APPENDIX A: Guidelines Guidelines for the Practice and Documentation of Comprehensive Medication Management in the Patient-Centered Medical Home Based on Information Contained in the PCPCC Resource Guide:
More informationHPSJ s Cognitive Services Program 07/2015
HPSJ s Cognitive Services Program 07/2015 Pharmacy & MTM Services Growing demand for MTM services Each year, inappropriate use of medications have led to $1.5 million dollars spent on preventable, medication-related
More informationPain Management Regulations Affect More Than Pain Management Specialists January 2012. Of counsel to
Pain Management Regulations Affect More Than Pain Management Specialists January 2012 LINDA A. KEEN MSN, JD, LHCRM LAW OFFICE OF LINDA A. KEEN P.A. TALLAHASSEE, FL Of counsel to Pain Management Regulations
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin
PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because
More informationProvision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine
Provision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine Guideline Updated: August 2010 Replaced: November 1998 To serve the public and guide the medical profession EDTA Chelation
More informationSCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE
SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE 1 P a g e The following Operational Guidance Manual has been prepared with input from both community and prison addictions specialists
More informationHAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES
Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute
More informationWhat Pharmacists Would Like Team Members to Know About Medication Therapy for Diabetes
What Pharmacists Would Like Team Members to Know About Medication Therapy for Diabetes 38 In this section, you will find an overview of key issues related to medication therapy management and diabetes
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationAgency # 070.00 REGULATION 9 PHARMACEUTICAL CARE/PATIENT COUNSELING
Agency # 070.00 REGULATION 9 PHARMACEUTICAL CARE/PATIENT COUNSELING 09-00: PATIENT COUNSELING 09-00-0001--PATIENT INFORMATION, DRUG USE EVALUATION, AND PATIENT COUNSELING The intent of this regulation
More informationSummary of new Medicare Benefits Schedule (MBS) item numbers: general practice and allied health. Updated April 2013
Summary of new Medicare Benefits Schedule (MBS) item numbers: general practice and allied health Updated April 2013 If you would like to receive this publication in an accessible format please phone (03)
More informationINDIGENOUS CHRONIC DISEASE PACKAGE CARE COORDINATION AND SUPPLEMENTARY SERVICES PROGRAM GUIDELINES
CLOSING THE GAP tackling disease INDIGENOUS CHRONIC DISEASE PACKAGE CARE COORDINATION AND SUPPLEMENTARY SERVICES PROGRAM GUIDELINES November 2012 CONTENTS 1. Introduction... 3 Program Context... 3 Service
More informationRequirements for Drug Information Centres
FIP Pharmacy Information Section Requirements for Drug Information Centres Summary All countries should provide drug information services either independently or as part of a regional network. The service
More informationMedication Policy and Procedures
Medication Policy and Procedures Policy Number: 2009/10 Approved by: Heritage Management Committee 10 November 2009 Last reviewed: October 2009 Next review due: November 2011 Policy Statement Studies of
More informationLEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
More informationPCNE Classification for Drug related problems
PCNE Classification for Drug related problems (revised 22-04-03 vm) V4.00 2003 Pharmaceutical Care Network Europe Foundation This classification can freely be used in Pharmaceutical Care Research and practice,
More informationHealth Professions Act BYLAWS SCHEDULE F. PART 3 Residential Care Facilities and Homes Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 3 Residential Care Facilities and Homes Standards of Practice Table of Contents 1. Application 2. Definitions 3. Supervision of Pharmacy Services in a Facility
More informationMEDICATION THERAPY ADHERENCE CLINIC : DIABETES
MEDICATION THERAPY ADHERENCE CLINIC : DIABETES PHARMACEUTICAL SERVICES DIVISION MINISTRY OF HEALTH MALAYSIA First Edition, 2010 Pharmaceutical Services Division Ministry of Health, Malaysia ALL RIGHT RESERVED
More informationGUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION
GUIDELINES GUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION Preamble The purpose of this document is to provide guidance for the pharmacist
More informationSummary of the risk management plan (RMP) for Cerdelga (eliglustat)
EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to
More informationOutpatient Prescription Drug Benefit
Outpatient Prescription Drug Benefit GENERAL INFORMATION This supplemental Evidence of Coverage and Disclosure Form is provided in addition to your Member Handbook and Health Plan Benefits and Coverage
More informationManaging Medicines Access Programs. Guiding principles for the governance of Medicines Access Programs in Australian hospitals
Managing Medicines Access Programs Guiding principles for the governance of Medicines Access Programs in Australian hospitals May 2015 Council of Australian Therapeutic Advisory Groups Address: c/ - NSW
More informationVildagliptin (Galvus) for type 2 diabetes
Vildagliptin (Galvus) for type 2 diabetes This Medicine Update is for people who are taking, or thinking about taking, vildagliptin. Summary Vildagliptin (brand name Galvus) is a new medicine. It is a
More informationPPP 1. Continuation of a medication to ensure continuity of care
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationPolicy for the issue of permits to prescribe Schedule 8 poisons
Policy for the issue of permits to prescribe Schedule 8 poisons May 2011 Introduction The Victorian Drugs, Poisons and Controlled Substances (DPCS) legislation sets out certain circumstances when a medical
More informationExenatide (Byetta) for type 2 diabetes
Exenatide (Byetta) for type 2 diabetes This Medicine Update is for people who are using, or thinking about using, exenatide. Summary Exenatide is a new injectable medicine that reduces blood glucose levels.
More informationNursing Guidelines. Management of Medicines. in Aged Care
Nursing Guidelines Management of Medicines in Aged Care Nursing Guidelines: Management of Medicines in Aged Care Author: Australian Nursing and Midwifery Federation (ANMF). Prepared by Julianne Bryce and
More informationHow To Prevent Medication Errors
The Academy of Managed Care Pharmacy s Concepts in Managed Care Pharmacy Medication Errors Medication errors are among the most common medical errors, harming at least 1.5 million people every year. The
More informationUnderstanding Alberta s Drug Schedules
Understanding Alberta s Drug Schedules Preface In May 2002, the provincial drug schedules to the Pharmaceutical Profession Act were amended. In April 2007, the Alberta Regulation 66/2007 to the Pharmacy
More informationSection II When you are finished with this section, you will be able to: Define medication (p 2) Describe how medications work (p 3)
Section II When you are finished with this section, you will be able to: Define medication (p 2) Describe how medications work (p 3) List the different medication effects (p5) List the ways that medications
More informationDoctor of Pharmacy Education Program-Level Ability-Based Outcomes North Dakota State University College of Pharmacy, Nursing, and Allied Sciences
Doctor of Pharmacy Education Program-Level Ability-Based Outcomes North Dakota State University College of Pharmacy, Nursing, and Allied Sciences The mission of North Dakota State University College of
More informationThe benefits of being in-house... An innovative model of care for palliative care nurse practitioners in Residential Aged Care
The benefits of being in-house... An innovative model of care for palliative care nurse practitioners in Residential Aged Care Peter Jenkin Nurse Practitioner What s my point? A palliative care nurse practitioner
More informationABC S OF MEDICATION THERAPY MANAGEMENT SERVICES. Eric Crumbaugh, PharmD
ABC S OF MEDICATION THERAPY MANAGEMENT SERVICES Eric Crumbaugh, PharmD Look familiar? Objectives Discuss the effects of the aging population on the current practice of community pharmacy. Identify current
More informationInhaler Technique Check
Protocol October 2015 Version 1.3 Table of Contents Service Information... 2 Service objective... 2 Clinical service overview... 2 Documentation... 3 Staff Roles... 3 Facilities to support the program...
More informationHow To Improve Safety
Medication safety in Australia an overview Margaret Duguid Pharmaceutical Advisor Australian Commission on Safety and Quality in Health Care 30 October 2009 Medication safety and quality Medications are
More informationEscitalopram (Lexapro) for major depressive disorder
Escitalopram (Lexapro) for major depressive disorder Summary PBS listing Reason for listing Place in therapy Restricted benefit: Major depressive disorders. Escitalopram was listed on the basis of cost-minimisation
More informationJoint Commission of Pharmacy Practitioners
Pharmacists Patient Care Process May 29, 2014 Joint Commission of Pharmacy Practitioners The Joint Commission of Pharmacy Practitioners (JCPP) was established in 1977 and serves as a forum on matters of
More informationGuidelines for Developing a Protocol/Procedure for the Administration of Medication
Appendix 1 Guidelines for Developing a Protocol/Procedure for the Administration of Medication The Child Care (Pre-School Services) (N0 2) Regulations 2006 and Explanatory Guide to Requirements and Procedures
More informationIntroduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationPrescription Drug Options for Older Adults: Managing Your Medicines
Prescription Drug Options for Older Adults: Managing Your Medicines As people age, the likelihood of taking medicines increases; studies show that the more medicines people take, the more likely they are
More informationNIMC VTE Prophylaxis Section Audit and Reporting Tool User Guide
NIMC VTE Prophylaxis Section Audit and Reporting Tool User Guide November 2013 Commonwealth of Australia 2013 This work is copyright. It may be reproduced in whole or in part for study or training purposes
More informationWest Midlands Centre for ADRs. Jeffrey Aronson. Robin Ferner. Side Effects of Drugs Annuals. Editor Meyler s Side Effects of Drugs
Do we have a common understanding of medication errors? Editor Meyler s Side Effects of Drugs Jeffrey Aronson Co-editor: Stephens Detection and Evaluation of Adverse Drug Reactions Side Effects of Drugs
More informationLicensed Pharmacy Technician Scope of Practice
Licensed Scope of Practice Adapted from: Request for Regulation of s Approved by Council April 24, 2015 Definitions In this policy: Act means The Pharmacy and Pharmacy Disciplines Act means an unregulated
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More informationFentanyl patches (Durogesic) for chronic pain
Fentanyl patches (Durogesic) for chronic pain FENT-a-nil Summary Oral morphine is preferred when an opioid is required for severe chronic pain, because of its familiarity, availability and the ease of
More informationMelatonin prolongedrelease. (Circadin) for insomnia
Melatonin prolongedrelease tablets (Circadin) for insomnia This Medicine Update is for people who are taking, or thinking about taking, prolongedrelease melatonin. Summary Melatonin prolonged-release tablets
More informationRivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.
South West Essex Rivaroxaban Shared Care Guideline (SCG) Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. Introduction
More informationAsthma, anxiety & depression
Anxiety and are common in people with asthma. The good news is that there are effective treatments both for asthma and for anxiety and. With careful management, the symptoms of anxiety and can be treated
More informationFOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE
www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.
More informationIncidence of drug related problems
Incidence of drug related problems Birthe Søndergaard Associate Professor. Faculty of Pharmaceutical Sciences. University of Copenhagen Disposition Drug related problems definition and classifications
More informationGood Practice Guidance: The administration of medicines in domiciliary care
Good Practice Guidance: The administration of medicines in domiciliary care Medicines Management Social Care Support Team Reviewed February 2014 This guidance is based on documents that were on CQC s website
More informationNurse Practitioners (NPs) and Physician Assistants (PAs): What s the Difference?
Nurse Practitioners (NPs) and Physician Assistants (PAs): What s the Difference? More than ever before, patients receive medical care from a variety of practitioners, including physicians, physician assistants
More informationGUIDELINES FOR COMMUNITY ALCOHOL DETOXIFICATION IN SHARED CARE
GUIDELINES FOR COMMUNITY ALCOHOL DETOXIFICATION IN SHARED CARE Dr Millicent Chikoore MBBS MRCPsych Dr O Lagundoye MBBS MRCPsych Community based alcohol detoxification is a safe and effective option for
More informationEnoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants
Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications
More informationOver-prescribing Excessive doses/duration of medicines Lacking indication. Mis-prescribing Unfavourable choice of medicine, dose, or duration
Inappropriate prescribing: STOPP-START criteria Clara Drenth-van Maanen, MD Clinical pharmacologist Risks outweighing benefits Inappropriate prescribing Over-prescribing Excessive doses/duration of medicines
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationPharmacists improving care in care homes
The Royal Pharmaceutical Society believes that better utilisation of pharmacists skills in care homes will bring significant benefits to care home residents, care homes providers and the NHS. Introduction
More informationAs You Age. Aging, Medicines, and Alcohol. A Guide to
As You Age A Guide to Aging, Medicines, and Alcohol U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Food and Drug Administration www.samhsa.gov Take
More informationTramadol Educational Resource Materials
Tramadol Educational Resource Materials Audit Materials November 2013 (Updated August 2014) These educational resource materials have been prepared by a multiprofessional collaborative group, with support
More informationDRUG INTERACTIONS: WHAT YOU SHOULD KNOW. Council on Family Health
DRUG INTERACTIONS: WHAT YOU SHOULD KNOW Council on Family Health Drug Interactions There are more opportunities today than ever before to learn about your health and to take better care of yourself. It
More information